TABLE 3

Potential vaccines in clinical trials for COVID-19 as of June 29, 2020

Sources: who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines; clinicaltrials.gov; clinicaltrialsregister.eu.

Vaccine categoryVaccine typeVaccine developerPhaseVaccine identifier
DNA basedDNA plasmid + electroporationInovio PharmaceuticalsPhase 1NCT04336410
DNA vaccine, GX-19Genexine ConsortiumPhase 1NCT04445389
Inactivated virusInactivatedBeijing Institute of Biologic ProductsPhase 1/2ChiCTR2000032459
InactivatedWuhan Institute of Biologic ProductsPhase 1/2ChiCTR2000031809
InactivatedSinovac Research & Development Co., LtdPhase 1/2NCT04352608
Phase 1/2NCT04383574
InactivatedChinese Academy of Medical SciencesPhase 1/2NCT04412538
Nonreplicating viral vectorAdenovirus type 5CanSino Biologic Inc; preliminary results (Zhu et al., 2020)Phase 1NCT04313127
Beijing Institute of BiotechnologyPhase 2ChiCTR2000031781
ChAdOx1-SUniversity of Oxford/AstraZenecaPhase 3 Phase 2/3ISRCTN89951424
Phase 2/32020-001228-32
Phase 1/2NCT04400838
Phase 1/22020-001072-15 NCT04324606
AdenoviralGamaleya Research InstitutePhase 1 Phase 1/2NCT04436471
NCT04437875
Adeno basedChinese Academy of Medical SciencesPhase 2NCT04341389 NCT04412538
Protein subunitRecombinant SARS-CoV-2 trimeric S protein subunitClover Biopharmaceuticals Inc./GSK/DynavaxPhase 1NCT04405908
Recombinant protein (RBD dimer)Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd/The Second Affiliated Hospital of Chongqing Medical University/Beijing Chao Yang HospitalPhase 1NCT04445194
Full length recombinant SARS CoV-2 glycoproteinnanoparticle vaccine adjuvanted with Matrix MNovavaxPhase 1/2NCT04368988
RNAMessenger RNA in lipid nanoparticleModerna/NIH/NIAID; related preclinical study (Corbett et al., 2020)Phase 1 Phase 2NCT04283461 NCT04405076
Messenger RNA in lipid nanoparticleBioNTech/Fosun Pharma/PfizerPhase 1/22020-001038-36
Phase 1NCT04368728
mRNACurevacPhase 1NCT04449276
mRNAPeople’s Liberation Army (PLA) Academy of Military Sciences/Walvax BiotechPhase 1ChiCTR2000034112
Self-amplifying RNA in lipid nanoparticleImperial College LondonPhase 1ISRCTN17072692
  • GSK, GlaxoSmithKline; NIAID, National Institute of Allergy and Infectious Diseases; NIH, National Institutes of Health.